Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

NCT02145403 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies
Relapse
Graft-Versus-Host Disease

Interventions

DRUG: Carfilzomib
DRUG: Tacrolimus

Sponsor

University of Michigan Rogel Cancer Center